Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CryoLife (CRY) stocks in Canada

Learn how to easily invest in CryoLife stocks.

CryoLife is a medical devices business based in the US. CryoLife stocks (CRY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $27.79 – an increase of 1.11% over the previous week. CryoLife employs 1,200 staff and has a trailing 12-month revenue of around $287.3 million.

How to buy shares in CryoLife

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CryoLife stock price (NYSE:CRY)

Use our graph to track the performance of CRY stocks over time.

CryoLife shares at a glance

Information last updated 2022-01-25.
Latest market close$18.18
52-week range$16.95 - $32.34
50-day moving average $19.19
200-day moving average $24.10
Wall St. target price$32.44
PE ratio 425.7143
Dividend yield $0.03 (0.17%)
Earnings per share (TTM) N/A

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy CryoLife stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CryoLife price performance over time

Historical closes compared with the close of $18.18 from 2022-01-25

1 week (2022-01-19) 1.11%
1 month (2021-12-22) N/A
3 months (2021-10-26) -13.96%
6 months (2021-07-26) -29.81%
1 year (2021-01-26) -27.71%
2 years (2020-01-24) -39.36%
3 years (2019-01-25) 27.97
5 years (2017-01-26) 18.25

Is CryoLife under- or over-valued?

Valuing CryoLife stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CryoLife's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CryoLife's P/E ratio

CryoLife's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 426x. In other words, CryoLife shares trade at around 426x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

CryoLife's PEG ratio

CryoLife's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 420.8333. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CryoLife's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

CryoLife's EBITDA

CryoLife's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $36.8 million.

The EBITDA is a measure of a CryoLife's overall financial performance and is widely used to measure a its profitability.

CryoLife financials

Revenue TTM $287.3 million
Operating margin TTM 4.5%
Gross profit TTM $167.8 million
Return on assets TTM 1.01%
Return on equity TTM 56.24%
Profit margin 0.63%
Book value $7.92
Market capitalisation $-99,999,990,000

TTM: trailing 12 months

CryoLife share dividends

We're not expecting CryoLife to pay a dividend over the next 12 months.

Have CryoLife's shares ever split?

CryoLife's shares were split on a 3:2 basis on 28 December 2000. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CryoLife shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for CryoLife shares which in turn could have impacted CryoLife's share price.

CryoLife share price volatility

Over the last 12 months, CryoLife's shares have ranged in value from as little as $16.95 up to $32.34. A popular way to gauge a stock's volatility is its "beta".

CRY.US volatility(beta: 1.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CryoLife's is 1.5302. This would suggest that CryoLife's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

CryoLife overview

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site